Venus Medtech prices HK IPO high, nabs $331m
Venus Medtech (Hangzhou), a Chinese biotechnology company, has wrapped up its Hong Kong IPO at the top end of guidance, raking in HK$2.6bn ($311.1m).
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts